Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Gains from Sales and Divestitures (2017 - 2020)

Historic Gains from Sales and Divestitures for Summit Therapeutics (SMMT) over the last 1 years, with Q4 2017 value amounting to $18.59.

  • Summit Therapeutics' Gains from Sales and Divestitures changed N/A to $18.59 in Q4 2017 from the same period last year, while for Dec 2017 it was $18.59, marking a year-over-year change of. This contributed to the annual value of $18.59 for FY2017, which is N/A changed from last year.
  • Latest data reveals that Summit Therapeutics reported Gains from Sales and Divestitures of $18.59 as of Q4 2017.
  • In the past 5 years, Summit Therapeutics' Gains from Sales and Divestitures registered a high of $18.59 during Q4 2017, and its lowest value of $18.59 during Q4 2017.